[Clinical relevance of homocysteine monitoring in the diabetic patient].
Accelerated atherosclerosis is common in diabetes mellitus, although its extent is not always related to its strong association with classical cardiovascular risk factors. Diabetic patients, especially with type 2 diabetes, are prone to cardiovascular disease which is the leading cause of death in this population. Recent clinical studies among general population have shown that an even mild increase of homocysteinemia play an important role in the progression of atherosclerosis, either in coronary or peripheral arteries. An increasing amount of in vitro data is providing evidence that excess of homocysteine has a toxic effect on the arterial wall. This aminoacid thus appears to be not only a risk marker but also an emerging cardiovascular risk factor. The measurement of plasma homocysteine contributes to the identification, among the diabetic population, of patients at high cardio-vascular risk, with the aim of improving their global management. Moreover the addition of group B vitamins provides an easy and low-cost treatment to lower hyperhomocysteinemia.
Benmerabet
S
S
Service de Diabétologie, CHU de Nice, Hôpital Pasteur, Nice, France. benmerabet.s@chu-nice.fr
Fredenrich
A
A
Robillon
J F
JF
Canivet
B
B
Candito
M
M
Van Obberghen
E
E
D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000150:complications*; D007328:Insulin / Q000502:physiology; D008991:Monitoring, Physiologic / Q000379:methods
D007328:Insulin; D006710:Homocysteine